Oliver Schnell, Germany
Forschergruppe Diabetes e.V. Helmholz ZentrumPresenter of 2 Presentations
ANALYSIS OF THE BUDGET IMPACT OF THE UTILISATION OF GLUCOSE METERS WITH COLOR-RANGE INDICATOR IN FIVE EUROPEAN HEALTHCARE SYSTEMS
Abstract
Background and Aims
Due to the increasing prevalence of diabetes worldwide, treatment and management costs of individuals with diabetes have become a major issue. Supporting self-management to improve glycaemic control by simplifying diabetes management is one way to address this aspect. The utilisation of blood glucose meters with colour-range indicator (CRI) has been shown to lower HbA1c. This budget impact analysis aimed at evaluating the financial impact of using a CRI-based glucose meter in five European countries: France, Germany, Italy, Spain and the UK.
Methods
Data from a randomised controlled trial, evaluating the effect of CRI-based glucose meters, were used to estimate the ten-year risk of patients for fatal myocardial infarction as calculated by the UKPDS risk engine. On the basis of assessed risks for myocardial infarction, the potential monetary impact for the five European healthcare systems was modelled.
Results
Based on a mean HbA1c reduction of 0.36%, as demonstrated in a randomised controlled trial using CRI-based glucose meters, the UKPDS risk engine estimated a 2.4% reduction of the ten-year risk of patients for fatal myocardial infarction. When applied to our economic model, substantial potential cost savings for the healthcare systems of five European countries were calculated: €547 472 (France), €9.0 million (Germany), €6.0 million (Italy), €841 799 (Spain), and €421 069 (United Kingdom) per year.
Conclusions
Utilisation of CRI-based glucose meters can aid the improvement of metabolic management in individuals with diabetes. In turn, this may also positively affect the expenditure of the healthcare systems on the complications of diabetes.
THE BURDEN OF SUB-OPTIMAL INSULIN INTENSIFICATION IN PEOPLE WITH TYPE 2 DIABETES: GLYCAEMIC CONTROL IN EUROPE
Abstract
Background and Aims
Target-optimised glycaemic management is important to minimise the risk of complications in type 2 diabetes (T2DM), impacting quality of life and healthcare expenditure. This work evaluates the current situation in Europe with regard to numbers treated with insulin, the proportion not achieving glycaemic target and therefore in need to advance insulin therapy.
Methods
We quantified the burden of insulin treated T2DM populations not at target for France, Germany, Italy, Netherlands, Spain and UK based on the available evidence, both from an epidemiological and economic perspective.
Results
In the six European countries, more than 64% of people with T2DM on insulin therapy have a HbA1c above the target of 7%. Studies report that up to 77% of persons with T2DM treated with basal insulin/basal insulin supported oral therapy (BOT) are above this target. Evidence on individuals on multiple daily injections (MDI, ≥2 injections per day) is more fragmented, although existing studies report similar or worse glycaemic control compared to those on BOT. We estimate that at least 2 million persons with T2DM on insulin therapy, both BOT and MDI, are above target, with an estimated economic impact of more than €28 billion per year in Europe.
Conclusions
When considering insulin therapy in the population with T2DM in Europe, approximately two-thirds do not achieve appropriate glycaemic control, increasing the risk of diabetes complications and related costs. Improving insulin therapy by various technological advancements may be a reasonable approach to decrease the epidemiological and economic burden of insulin treated individuals with T2DM.